2001
DOI: 10.1055/s-2001-18563
|View full text |Cite
|
Sign up to set email alerts
|

Hypersensitivitätssyndrom unter Therapie mit Allopurinol bei asymptomatischer Hyperurikämie mit tödlichem Ausgang

Abstract: The life threatening hypersensitivity syndrome with fever, eosinophilia, hepatitis, renal failure and skin eruptions as severe as epidermal necrolysis is the most dangerous complication of therapy with allopurinol. The trigger seems to be oxipurinol, the main metabolite of allopurinol, which particularly accumulates in patients with renal failure and concomitant therapy with thiazides. There is no specific treatment of the disease. The use of allopurinol in patients with asymptomatic hyperuricaemia is not indi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0

Year Published

2002
2002
2017
2017

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 28 publications
(8 citation statements)
references
References 17 publications
0
8
0
Order By: Relevance
“…However, its usage is limited by hypersensitivity problems (Hammer et al. 2001 ), Stevens–Johnson syndrome (Fritsch and Sidoroff 2000 ), renal toxicity (Horiuchi et al. 2000 ) and even fatal liver necrosis (Pereira et al.…”
Section: Introductionmentioning
confidence: 99%
“…However, its usage is limited by hypersensitivity problems (Hammer et al. 2001 ), Stevens–Johnson syndrome (Fritsch and Sidoroff 2000 ), renal toxicity (Horiuchi et al. 2000 ) and even fatal liver necrosis (Pereira et al.…”
Section: Introductionmentioning
confidence: 99%
“…Allopurinol is a potent XO inhibitor with a purine backbone and has been used clinically for more than 40 years (Murata et al 2009 ). Unfortunately, this drug has infrequent and severe side effects as in the cause of hypersensitivity syndrome (Hammer et al 2001 ), Stevens–Johnson syndrome (Fritsch and Sidoroff 2000 ), and renal toxicity (Horiuchi et al 2000 ). Therefore, there is a need to develop other novel chemical structural types of XO inhibitors.…”
Section: Introductionmentioning
confidence: 99%
“…Some hypouricemic agents, including uricosuric agents and xanthine oxidase inhibitors, are available [3]; however, adverse effects such as gastrointestinal irritation, bone marrow suppression, renal toxicity and hypersensitivity syndromes always limit their clinical uses [4,5]. Therefore, it is very important to search for better hypouricemic medicines.…”
Section: Introductionmentioning
confidence: 99%